NEK9 ablation rewires docetaxel resistance through induction of ERK-mediated cancer cell pyroptosis
Shamima Azma Ansari, Sibasish Mohanty, Pallavi Mohapatra, Sudeshna Datta, Mamuni Swain, Rachna Rath, Dillip Kumar Muduly, S. K. D. Majumdar, Rajeeb Kumar Swain, Sunil K. Raghav, Rupesh Dash
This study identifies NEK9 as a driver of docetaxel resistance in cancers and shows that its ablation sensitizes cells to docetaxel via ERK-mediated pyroptosis, suggesting fostamatinib as a potential therapeutic partner.
British Journal of Cancer · Sep 9, 2025Peer-reviewedCancer Biology